bioRxiv Science⌕ Search

Biology subjects

Fahraeus, R.

Publications and source records attributed to Fahraeus, R..

5 recordsLinked to original sources

Tracing the expansion of p53 retrogenes in elephant species: A foundation for functional insights.

Elephants have evolved multiple TP53 copies through a retrotransposition event followed by successive duplications. Some of these TP53 retrogenes (RTGs) are expressed and hypothesized to have functional roles in cellular regulation. However, comparative genomic studies on TP53 evolution and function are limited due to scarce genomic data for elephants and other afrotherians. Most existing research relies on scaffold assemblies of Loxodonta africana (LoxAfr3 and LoxAfr4), with some focus on Elephas maximus chromosomal assembly. In this in silico study, we analyzed three elephant genomes to validate TP53 RTGs, assess their copy variation, and trace their evolution. For the first time we describe 29 TP53 RTGs in E. maximus versus 18-19 in L. africana. These copies show sequence variation, especially in the duplicated regions and their flanking repetitive elements. Chromosomal mapping in E. maximus revealed that two major classes of TP53 RTGs are consistently arranged in pairs on chromosome 27, which harbours 27 of the 29 identified copies. The observed distribution strongly supports an evolutionary model in which large-scale genomic segments, each encompassing at least two retrogenes of different groups, were duplicated early in the elephant lineage, driving the extensive amplification of TP53 RTGs, as suggested also by the patterns of the flanking repetitive elements. The TP53 RTGs expansion was followed by a unique inversion on chromosome 27 that separates the duplication clusters. Thus, this study enhances our understanding of the elephants multi-p53 system, linked to cancer resistance, body size, and Petos paradox, and supports ongoing research into functional aspects. Significance StatementThis study uncovers the complex genomic architecture of elephant TP53 RTGs, which have diversified into two phylogenetically distinct types present in both African and Asian elephants. While both species share these 2 types, they differ substantially in copy number (18 in African versus 28 in Asian elephants), and in sequence variation, highlighting lineage-specific evolutionary trajectories. Detailed sequence analyses of the chromosomal organization of these copies in the Elephas maximus high-quality genome assembly, particularly the cluster on chromosome 27, indicates that they arose from stepwise duplications of extended genomic segments, which likely facilitated both the expansion and regulatory diversification of the TP53 RTGs repertoire. Comparative analysis with other mammals reveals an elephant-specific inversion that reorganized the expanded TP53 RTGs copies, creating a new genomic configuration that could have influenced the regulation and expression of some of the p53 RTGs. Therefore, this work advances our understanding of how evolutionary pressures shaped the landscape of TP53 RTGs and their flanking genetics elements in elephants. By identifying accurately the retrogene copy numbers, sequences and putative functional domains, it establishes a critical foundation for future studies investigating their functional roles in DNA damage and genome stability.

evolutionary biology↗

Cancer-associated synonymous mutations reveal stress signal-dependent mRNA folding that selectively modulates protein function.

Recent technical advances have facilitated studies on changes in mRNA structures in response to signaling pathways. However, if mRNA structures can affect the function of the encoded protein remains poorly understood. In-cell RNA structural probing (SHAPE-MaP) demonstrates how two cancer-associated synonymous mutations (CASMs) at proline codon 34 (c.102 C>A and c.102 C>G) prevent DNA damage-induced TP53 mRNA folding, whereas the non-cancer-associated c.102C>U mutation does not. Transcript and chromatin immunoprecipitation (ChIP) analysis reveal that p53 expressed from CASM34 has reduced promoter binding and reduced induction of p53 downstream target genes PUMA and 14-3-3-{sigma}, but not p21CDKN1A. Transcriptome analysis reveals a CASM34-mediated global attenuation of DNA damage-responsive gene expression. Together, the results demonstrate that CASM34 interferes with signal-induced p53 mRNA folding during DNA damage, leading to selective modulation of protein activity. More broadly, our findings highlight a general concept by which cancer-associated synonymous mutations target signal-induced mRNA structures that influence the encoded protein. Significance statementRecent studies have revealed that synonymous mutations can target RNA metabolism and are associated with numerous diseases; however, how these mutations affect the function of the encoded protein remain unclear. Using in-cell RNA structural probing, we show that two cancer-associated synonymous mutations in TP53 disrupt DNA damage-induced folding of p53 mRNA. These mutations selectively impair p53 promoter binding and transcriptional activation of specific downstream target genes. Our results demonstrate that disruption of signal-induced mRNA folding by synonymous mutations can modulate the activity of the encoded protein. More broadly, this work identifies signal-responsive mRNA structures as functional targets of cancer-associated synonymous mutations.

molecular biology↗

Major Histocompatibility Complex class I heavy chains localize in both cytoplasmic and nuclear compartment

The Major Histocompatibility Complex class I (MHC-I) molecules present antigenic peptides (AP) to CD8+ T cells for self versus non-self recognition. Loading of AP on MHC-I takes place in the endoplasmic reticulum (ER), upon shuttling of cytoplasmic AP substrates to the ER. Understanding of this process has been influenced by the view that MHC-I antigens are produced from the proteasomal degradation of cellular proteins. Recent observations on the intronic and untranslated region-derived peptides as well as on the non-AUG translation products presented on the MHC-I open the possibility that antigenic peptides can derive from pre-spliced mRNAs translated in the nuclear compartment. In this brief report, we show that a fraction of human MHC-I molecules (human leukocyte antigens type A, HLA-A) is present in the nuclei of cells, in the proximity of histone H2B. With this finding, we hope to initiate a new direction of research on the nuclear role of MHC-I and ask whether the loading of antigens can take place in the nuclear compartment.

immunology↗

Keap1-resistant ΔN-Nrf2 isoform does not translocate to the nucleus upon electrophilic stress

The Nrf2 pathway is an essential defense pathway in a cell. It responds to oxidative and electrophilic stress via derepression of Nrf2 from Keap1-Cul3-mediated degradation, accumulation of Nrf2 in the nucleus and transcriptional activation of a number of detoxifying and cell protective Nrf2 target genes. Here we report that normal and cancer cells also express the N-terminally truncated Nrf2 isoform ({Delta}N-Nrf2), which originates from an alternative promoter. Co-immunoprecipitation together with molecular dynamics simulation showed that the binding between {Delta}N-Nrf2 and Keap1 is impaired, resulting in the much higher stability of this form. {Delta}N-Nrf2 is retained in the cytoplasm in response to electrophilic stress, indicating that it does not regulate transcription under the same stress stimuli as the full-length Nrf2. Altogether this data suggests that Nrf2 has other functions in cells than transcriptional activation of genes, which most probably rely on the protein-protein interactions in the cytoplasm. The regulation between these functions takes place on the level of transcription. Significance StatementThis work signifies the importance of alternative transcription in assigning the function to the produced protein. Nrf2 transcripts produced from the second promoter of the Nrf2 gene give rise to the N-terminally truncated Nrf2 form ({Delta}N-Nrf2), which is retained in the cytoplasm upon stress, thus it has a different role in cells than transcriptional regulation. {Delta}N-Nrf2 is resistant to the Keap1-Cul3 degradation pathway and is highly expressed in all tested cell types. This work points to the new, cytoplasmic role of Nrf2 in cells, determined at the level of transcription.

cell biology↗

A comprehensive library of canonical and non-canonical MHC class I antigens for cancer vaccine development.

A longstanding disconnect between the growing number of MHC Class I immunopeptidomic studies and genomic medicine hinders cancer vaccine design. We develop COD-dipp to genomically map the full spectrum of detected canonical and non-canonical (non-exonic) MHC Class I antigens from 26 cancer studies. We demonstrate that patient mutations in regions overlapping physically identified antigens better predict immunotherapy response when compared to neoantigen predictions. We suggest a vaccine design approach using 140,966 highly immune-visible regions of the genome annotated by their expression and haplotype frequency in the human population. These regions tend to be highly conserved, mutated in cancer and harbor 7.8 times more immunogenicity. Intersecting pan-cancer mutations with these immune surveilled regions revealed a potential to create off-the-shelf multi-epitope vaccines against public neoantigens. Here we release COD-dipp, a cancer vaccine toolkit as a web-application (https://www.proteogenomics.ca/COD-dipp) and open-source high-throughput resource.

bioinformatics↗